ADMA Biologics, Inc. (ADMA) Q3 2016 Earnings Results

ADMA BioLogics Inc Beats on EPS, Stock Up 4.06%

ADMA BioLogics reported a narrower-than-expected loss per share, which contributed to a positive stock reaction, with shares rising 4.06%. The lack of revenue data leaves some uncertainty, but the EPS beat suggests potential improvements in financial performance. Investors may view this as a sign of progress in the company's operations.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.34	N/A	+13.92%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding their performance. They emphasized their commitment to improving the company's financial health.

Management expressed satisfaction with the EPS performance despite not providing revenue figures.

They highlighted ongoing efforts to enhance operational efficiency.

ADMA BioLogics Inc Beats on EPS, Stock Up 4.06%

Key numbers

Management commentary

ADMA Biologics, Inc.

More earnings this week

ADMA BioLogics Inc Beats on EPS, Stock Up 4.06%

Key numbers

Management commentary